| Literature DB >> 34140865 |
Mostafa S Ali1, Heba G Abd El-Aziz1.
Abstract
OBJECTIVE: Reduced muscle and bone mass, improper muscle function, and varying degrees of mobility dysfunctions are the main complications of cerebral palsy (CP). Many children with CP also present with poor abdominal muscle activation. Whole-body vibration (WBV) is a unique approach for enhancing strength and motor abilities in several clinical conditions. This study aimed to determine the influence of a 12-week WBV intervention on the thickness of the abdominal muscles and the sitting ability of children with diplegia.Entities:
Keywords: Abdominal thickness; Cerebral palsy; Diplegia; Sitting ability; Whole-body vibration
Year: 2020 PMID: 34140865 PMCID: PMC8178633 DOI: 10.1016/j.jtumed.2020.11.006
Source DB: PubMed Journal: J Taibah Univ Med Sci ISSN: 1658-3612
Figure 1Flowchart of patient randomisation.
Demographic characteristics of both groups.
| Control group (n = 15) | Study group (n = 15) | t value | P value | |
|---|---|---|---|---|
| Age (years) | 5.23 ± 0.70 | 4.87 ± ± 0.67 | 1.464 | 0.154 (NS) |
| Sex | ||||
| 7 (46.7%) | 6 (40.0%) | χ2 = 0.136 | 0.713 (NS) | |
| 8 (53.3%) | 9 (60.0%) | |||
Data are expressed as mean ± SD or number (%). χ2, Chi-square test; NS (P > 0.05), not significant.
Comparison of mean abdominal muscle thickness values between both groups (pre- and post-treatment).
| Control group (n = 15) | Study group (n = 15) | F value | Cohen Effect size | P value | |
|---|---|---|---|---|---|
| 0.35 ± 0.07 | 0.32 ± 0.04 | 1.248 | 0.52 | 0.273 (NS) | |
| 0.37 ± 0.07 | 0.42 ± 0.04 | 38.783 | 0.87 | 0.001 (S) | |
| 0.02 & 5.71% ↑↑ | 0.10 & 31.25% ↑↑ | ||||
| Cohen Effect size | 0.45 | 2.5 | |||
| −2.346 & 0.034 (S) | −15.178 & 0.001 (S) | ||||
| 0.48 ± 0.04 | 0.46 ± 0.03 | 2.347 | 0.56 | 0.137 (NS) | |
| 0.51 ± 0.04 | 0.54 ± 0.03 | 99.547 | 0.84 | 0.001 (S) | |
| 0.03 & 6.25 ↑↑ | 0.08 & 17.39 ↑↑ | ||||
| Cohen Effect size | 0.75 | 2.66 | |||
| −17.748 & 0.001 (S) | −18.558 & 0.001 (S) | ||||
| 0.32 ± 0.05 | 0.31 ± 0.03 | 0.085 | 0.24 | 0.773 (NS) | |
| 0.35 ± 0.04 | 0.40 ± 0.02 | 111.557 | 1.58 | 0.001 (S) | |
| 0.03 & 9.37 ↑↑ | 0.09 & 29.03 ↑↑ | ||||
| Cohen Effect size | 0.65 | 3.4 | |||
| −21.313 & 0.001 (S) | −15.781 & 0.001 (S) | ||||
| 0.68 ± 0.05 | 0.67 ± 0.03 | 0.038 | 0.24 | 0.846 (NS) | |
| 0.71 ± 0.05 | 0.77 ± 0.02 | 129.940 | 1.42 | 0.001 (S) | |
| 0.03 & 4.41 ↑↑ | 0.100 & 14.93 ↑↑ | ||||
| Cohen Effect size | 0.6 | 3.77 | |||
| −15.838 & 0.001 (S) | −19.571 & 0.001 (S) | ||||
Data are expressed as mean ± SD.
MD, mean difference; F value, ANCOVA test; t value, paired t-test; NS (P > 0.05), not significant; S (P < 0.05), significant.
Comparison between the mean values of sitting domain and GMFM-88 in both groups (pre- and post-treatment).
| Control group (n = 15) | Study group (n = 15) | F value | Cohen Effect size | P value | |
|---|---|---|---|---|---|
| Pre-treatment | 48.01 ± 8.55 | 46.04 ± 5.84 | 0.038 | 0.26 | 0.846 (NS) |
| Post-treatment | 53.03 ± 4.98 | 59.58 ± 3.04 | 129.940 | 1.58 | 0.001 (S) |
| Mean difference | 5.02 | 13.54 | |||
| % change | 10.46 ↑↑ | 29.41 ↑↑ | |||
| Cohen Effect size | 0.67 | 2.67 | |||
| t## value | −3.700 | −11.430 | |||
| p value | 0.002 (S) | 0.001 (S) | |||
Data are expressed as mean ± SD.
F value, ANCOVA test; t value, paired t-test; NS (P > 0.05), not significant; S, (P < 0.05), significant.